Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1997-12-19
1999-11-09
Russel, Jeffrey E.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
530409, 530410, C07K 1113, C07K 1456
Patent
active
059817097
ABSTRACT:
A process for preparing .alpha.-interferon-polymer conjugates having high levels of retained interferon activity and relatively long circulating lives in vivo is disclosed. The process includes forming substantially non-antigenic .alpha.-interferon-polymer conjugates, combining the .alpha.-interferon-polymer conjugates with a sufficient amount of an acid to reduce the pH of the conjugates to a level which is sufficient to cleave the polymer linkages in an active site area of the interferon and thereafter adjusting the .alpha.-interferon-polymer conjugates to a physiologically-acceptable pH. Methods of treating interferon-susceptible conditions with the compositions of the present invention are also disclosed.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4766106 (1988-08-01), Katre et al.
patent: 4810638 (1989-03-01), Albarella et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4917888 (1990-04-01), Katre et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5109120 (1992-04-01), Ueno et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5281698 (1994-01-01), Nitecki
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5559213 (1996-09-01), Hakimi et al.
patent: 5646242 (1997-07-01), Baker et al.
patent: 5650234 (1997-07-01), Dolence et al.
patent: 5676942 (1997-10-01), Testa et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5747646 (1998-05-01), Hakimi et al.
Goeddel, D.V. et al., The Structure of Eight Distinct Cloned Human Leukocyte Interferon cDNAsNature, vol. 290; pp. 20-26; Mar. 5, 1981.
Zalipsky, S. et al., Attachment of Drugs to Polyethylene Glycols Eur. Polym. J., vol. 19, No. 12; pp. 1177-1183; 1983.
Zalipsky S. et al., Evaluation of a New Reagent for Covalent Attachment of Polyethylene Glycol to Proteins Biotechnology and Applied Biochemistry, vol. 15; pp. 100-114; 1992.
Kontsek, P., Human Type I Interferons: Structure and Function, Acta Virologica, vol. 38; pp. 345-360; 1994.
Kinstler, O.B. et al., Characterization and Stability of N-terminally PEGylated rhG-CSF, Pharmaceutical Res., vol. 13, No. 7; pp. 996-1002; 1996.
Monkarsh, S.P. et al., Positional Isomers of Monopegylated Interferon alpha-2a: Isolation, Characterization, and Biological Activity , Analytical Biochemistry, vol. 247; pp. 434-440; 1997.
Viscomi, G.C., Structure-activity of Type I Interferons, Biotherapy, vol. 10; pp. 59-86; 1997.
Gotoh, Y., et al. Chemical Modification of Silk Fibroin with Cyanuric Chloride-Activated Poly(ethylene glycol): Analysis of Reaction by H-NMR Spectroscop and . . . Bioconjugate Chem, vol. 4; pp. 554-559; 1993.
Lundblad, R.L., et al. Chemical Reagents for Protein Modification , CRC Press, Inc., vol . 1; pp. 105-125; 1988.
Shearwater Polymers, Inc. Catalog , p. 45; Jan. 1996.
Gilbert Carl W.
Greenwald Richard B.
Enzon Inc.
Russel Jeffrey E.
LandOfFree
.alpha.-interferon-polymer-conjugates having enhanced biological does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with .alpha.-interferon-polymer-conjugates having enhanced biological, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and .alpha.-interferon-polymer-conjugates having enhanced biological will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1457660